Form 4: Protagonist Therapeutics Director Acquires Shares and Options

Director Lewis T. Williams acquired 5,130 shares of common stock and 6,584 stock options in Protagonist Therapeutics on January 2, 2025.

Summary

• Lewis T. Williams, a director at Protagonist Therapeutics, acquired 5,130 shares of common stock on January 2, 2025.
• These shares were granted as restricted stock units, which will vest on January 15, 2026, contingent on continued service.
• Williams also acquired 6,584 stock options on the same date, with an exercise price of $38.98 per share.
• The stock options vest in 12 equal monthly installments starting January 2, 2025, also subject to continued service.
• The stock options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally positive as it shows alignment of interests between management and shareholders. The vesting schedule also indicates a long-term commitment.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.
• The vesting schedule for both shares and options incentivizes continued service and commitment from the director.

Future Outlook

The vesting of the shares and options is contingent on the director's continued service to the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders acquire or dispose of company securities. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units and stock options is typical for executive compensation packages in the biotechnology industry.
• The exercise price of $38.98 for the stock options is a common practice, often set at or above the market price at the time of grant.
• Similar filings are regularly made by directors and officers of comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• The acquisition of shares and options by a director can be viewed positively by shareholders, as it aligns the director's interests with the company's performance.
• The vesting schedule encourages the director's continued service, which benefits the company and its stakeholders.

Key Dates

Keywords

Protagonist Therapeutics, stock options, restricted stock units, insider trading, share acquisition, director, equity